Unity Biotechnology, Inc. (0YC0.L)
USD 1.02
(-1.45%)
USD 1.02
(-1.45%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 23.53 Million USD | -37.86% |
| 2022 | 37.88 Million USD | -21.9% |
| 2021 | 48.5 Million USD | -17.76% |
| 2020 | 58.97 Million USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 45 Thousand USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 22.6 Million USD | 0.0% |
| 2024 Q3 | 20.69 Million USD | 0.0% |
| 2024 Q2 | 21.65 Million USD | 0.0% |
| 2023 Q4 | 23.53 Million USD | -3.65% |
| 2023 Q1 | 34.04 Million USD | -10.12% |
| 2023 FY | 23.53 Million USD | -37.86% |
| 2023 Q2 | 29.37 Million USD | -13.71% |
| 2023 Q3 | 24.43 Million USD | -16.84% |
| 2022 Q1 | 43.87 Million USD | -9.55% |
| 2022 FY | 37.88 Million USD | -21.9% |
| 2022 Q4 | 37.88 Million USD | -7.73% |
| 2022 Q3 | 41.05 Million USD | -0.46% |
| 2022 Q2 | 41.24 Million USD | -5.99% |
| 2021 Q1 | 57.96 Million USD | -1.72% |
| 2021 Q4 | 48.5 Million USD | -11.74% |
| 2021 Q2 | 56.92 Million USD | -1.79% |
| 2021 FY | 48.5 Million USD | -17.76% |
| 2021 Q3 | 54.95 Million USD | -3.47% |
| 2020 FY | 58.97 Million USD | 0.0% |
| 2020 Q2 | 36.77 Million USD | -2.95% |
| 2020 Q1 | 37.88 Million USD | 0.0% |
| 2020 Q3 | 59.94 Million USD | 63.03% |
| 2020 Q4 | 58.97 Million USD | -1.62% |
| 2019 FY | - USD | -100.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | -100.0% |
| 2019 Q2 | 7000.00 USD | -73.08% |
| 2019 Q1 | 26 Thousand USD | -42.22% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 45 Thousand USD | 0.0% |
| 2018 Q4 | 45 Thousand USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | 3.418% |
| Dynavax Technologies Corporation | 252.41 Million USD | 90.675% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 29.091% |
| Perrigo Company plc | 3.63 Billion USD | 99.352% |
| Illumina, Inc. | 1.48 Billion USD | 98.419% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.925% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -2253.9% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.707% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.818% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 86.453% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.129% |
| Waters Corporation | 2.3 Billion USD | 98.979% |
| Biogen Inc. | 7.18 Billion USD | 99.673% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 29.766% |
| Evolus, Inc. | 120.35 Million USD | 80.443% |
| Adicet Bio, Inc. | 17.7 Million USD | -32.966% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 36.517% |
| bluebird bio, Inc. | 224.41 Million USD | 89.511% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 95.307% |
| FibroGen, Inc. | 89.69 Million USD | 73.757% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.139% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -626.819% |
| Homology Medicines, Inc. | 43.17 Million USD | 45.481% |
| Geron Corporation | 35.05 Million USD | 32.844% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 98.995% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 93.931% |
| Myriad Genetics, Inc. | 130.9 Million USD | 82.018% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -2414.85% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 75.67% |
| Zoetis Inc. | 6.56 Billion USD | 99.641% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -434.734% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 98.808% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 96.031% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 96.752% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 31.152% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 98.319% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 48.484% |
| Verastem, Inc. | 40.08 Million USD | 41.279% |
| Nektar Therapeutics | 112.62 Million USD | 79.1% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 86.781% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -665.745% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 97.922% |
| OPKO Health, Inc. | 222.03 Million USD | 89.398% |
| Exelixis, Inc. | 189.94 Million USD | 87.607% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 90.887% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | 81.902% |
| Imunon, Inc. | 1.13 Million USD | -1966.106% |
| Blueprint Medicines Corporation | 610.96 Million USD | 96.147% |
| Insmed Incorporated | 1.19 Billion USD | 98.027% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 98.43% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 58.695% |
| TG Therapeutics, Inc. | 100.11 Million USD | 76.489% |
| Incyte Corporation | 29.16 Million USD | 19.282% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 94.728% |